Drug intelligence / Profile preview

human chorionic gonadotropin + GnRH agonist

Development stage
Unknown
Lead developer
Embryolab Fertility Clinic
Modality
Peptides, Recombinant Proteins and Enzymes
Administration
Subcutaneous, Intramuscular
01

Overview

Human chorionic gonadotropin + GnRH agonist is a combination pharmacological regimen used as a 'dual trigger' for final oocyte maturation in assisted reproductive technology (ART). This protocol, specifically studied by Embryolab Fertility Clinic, involves the administration of hCG alongside a GnRH agonist to induce ovulation. hCG serves as a long-acting analog of Luteinizing Hormone (LH), binding to the LH/hCG receptor to promote oocyte maturation and luteinization. The GnRH agonist component triggers a 'flare' effect, causing the pituitary gland to release endogenous LH and Follicle-Stimulating Hormone (FSH). This dual approach aims to more closely replicate the natural mid-cycle gonadotropin surge compared to hCG alone, potentially improving maturation rates and embryo quality in patients with a history of suboptimal response to single-agent triggers.

Other names
Dual triggerhCG + GnRH-aDual trigger (hCG + GnRH agonist)
02

Targets

TSHR (Thyroid-stimulating hormone receptor)GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on human chorionic gonadotropin + GnRH agonist.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on human chorionic gonadotropin + GnRH agonist.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call